Curis Advances AML Treatment with Emavusertib, Showing Promising Clinical Results
- Curis presents promising emavusertib data for AML patients with minimal residual disease at the 67th ASH Annual Meeting.
- The combination of emavusertib with venetoclax and azacitidine shows increased undetectable MRD rates, rising to 62.5%.
- Curis is exploring emavusertib for other conditions and has received Orphan Drug Designation in the U.S. and Europe.
Curis Inc. Advances AML Treatment with Promising Emavusertib Data
Curis, Inc., a biotechnology firm known for its innovative treatments, presents updated clinical results from its ongoing study of emavusertib (CA-4948) at the 67th ASH Annual Meeting. This study focuses on patients with Acute Myeloid Leukemia (AML) who have achieved complete remission but remain minimal residual disease (MRD)-positive. Emavusertib is an oral inhibitor targeting IRAK4 and FLT3, and its combination with venetoclax and azacitidine (referred to as the ven-aza regimen) demonstrates encouraging efficacy in a particularly challenging subset of AML patients. The latest data shows that the proportion of patients achieving undetectable MRD (uMRD) has risen from 50% in July 2025 to 62.5% by October 12, 2025.
The results underscore the potential of emavusertib to enhance treatment outcomes in patients who are at risk of relapse despite achieving initial remission. Curis's CEO, James Dentzer, emphasizes the importance of these findings, advocating for further investigation into the triplet combination to optimize dosing and safety profiles. Such advancements are critical as AML treatment continues to evolve, particularly for patients who are MRD-positive and require new therapeutic strategies to maintain remission. Curis's commitment to refining the triplet regimen could provide significant benefits in terms of patient management and long-term outcomes.
Beyond the AML study, Curis is also exploring the capabilities of emavusertib in additional contexts, including relapsed/refractory primary central nervous system lymphoma and high-risk myelodysplastic syndrome through the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 studies. The drug has received Orphan Drug Designation from regulatory bodies in both the U.S. and Europe, underscoring its potential in addressing unmet medical needs in these serious conditions. Curis's collaboration with Aurigene Discovery Technologies Limited ensures that they have the exclusive rights to this promising therapeutic, positioning the company as a key player in the oncology landscape.
As the clinical landscape for AML continues to evolve, Curis's focus on emavusertib represents a significant stride toward improving patient outcomes. With further studies planned and ongoing investigations into its efficacy across various malignancies, Curis is poised to contribute meaningfully to the fight against aggressive hematologic cancers. For more details about their pipeline and research, interested parties can visit Curis's website.
